Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nozomu Kurose is active.

Publication


Featured researches published by Nozomu Kurose.


Annals of the Rheumatic Diseases | 2009

Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders

Yasufumi Masaki; Lingli Dong; Nozomu Kurose; Kazuko Kitagawa; Yuko Morikawa; Motohisa Yamamoto; Hiroki Takahashi; Yasuhisa Shinomura; Kohzoh Imai; Takako Saeki; Atsushi Azumi; Shinji Nakada; Eiji Sugiyama; Shoko Matsui; Tomoki Origuchi; Susumu Nishiyama; Isao Nishimori; Takayuki Nojima; Kazunori Yamada; Mitsuhiro Kawano; Yoh Zen; Masahiko Kaneko; Kana Miyazaki; Kazuo Tsubota; Katsumi Eguchi; Kouichi Tomoda; Toshioki Sawaki; Takafumi Kawanami; Masao Tanaka; Toshihiro Fukushima

Background: Mikulicz’s disease (MD) has been considered as one manifestation of Sjögren’s syndrome (SS). Recently, it has also been considered as an IgG4-related disorder. Objective: To determine the differences between IgG4-related disorders including MD and SS. Methods: A study was undertaken to investigate patients with MD and IgG4-related disorders registered in Japan and to set up provisional criteria for the new clinical entity IgG4-positive multiorgan lymphoproliferative syndrome (IgG4+MOLPS). The preliminary diagnostic criteria include raised serum levels of IgG4 (>135 mg/dl) and infiltration of IgG4+ plasma cells in the tissue (IgG4+/IgG+ plasma cells >50%) with fibrosis or sclerosis. The clinical features, laboratory data and pathologies of 64 patients with IgG4+MOLPS and 31 patients with typical SS were compared. Results: The incidence of xerostomia, xerophthalmia and arthralgia, rheumatoid factor and antinuclear, antiSS-A/Ro and antiSS-B/La antibodies was significantly lower in patients with IgG4+MOLPS than in those with typical SS. Allergic rhinitis and autoimmune pancreatitis were significantly more frequent and total IgG, IgG2, IgG4 and IgE levels were significantly increased in IgG4+MOLPS. Histological specimens from patients with IgG4+MOLPS revealed marked IgG4+ plasma cell infiltration. Many patients with IgG4+MOLPS had lymphocytic follicle formation, but lymphoepithelial lesions were rare. Few IgG4+ cells were seen in the tissue of patients with typical SS. Thirty-eight patients with IgG4+MOLPS treated with glucocorticoids showed marked clinical improvement. Conclusion: Despite similarities in the involved organs, there are considerable clinical and pathological differences between IgG4+MOLPS and SS. Based on the clinical features and good response to glucocorticoids, we propose a new clinical entity: IgG4+MOLPS.


Modern Rheumatology | 2012

A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details

Hisanori Umehara; Kazuichi Okazaki; Yasufumi Masaki; Mitsuhiro Kawano; Motohisa Yamamoto; Takako Saeki; Shoko Matsui; Takayuki Sumida; Tsuneyo Mimori; Yoshiya Tanaka; Kazuo Tsubota; Tadashi Yoshino; Shigeyuki Kawa; Ritsuro Suzuki; Tsutomu Takegami; Naohisa Tomosugi; Nozomu Kurose; Yasuhito Ishigaki; Atsushi Azumi; Masaru Kojima; Shigeo Nakamura; Dai Inoue

IgG4-related disease (IgG4RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. IgG4RD may be present in a certain proportion of patients with a wide variety of diseases, including Mikulicz’s disease, autoimmune pancreatitis, hypophysitis, Riedel thyroiditis, interstitial pneumonitis, interstitial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pseudotumor. Although IgG4RD forms a distinct, clinically independent disease category and is attracting strong attention as a new clinical entity, many questions and problems still remain to be elucidated, including its pathogenesis, the establishment of diagnostic criteria, and the role of IgG4. Here we describe the concept of IgG4RD and up-to-date information on this emerging disease entity.


Arthritis & Rheumatism | 2011

Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants.

Troy E. Daniels; Darren P. Cox; Caroline H. Shiboski; Morten Schiødt; Ava J. Wu; Hector Lanfranchi; Hisanori Umehara; Yan Zhao; Stephen Challacombe; Mi Y. Lam; Yvonne De Souza; Julie Schiødt; Helena Holm; Patricia A. M. Bisio; Mariana S. Gandolfo; Toshioki Sawaki; Mengtao Li; Wen Zhang; Beni Varghese-Jacob; Per Ibsen; Alicia Keszler; Nozomu Kurose; Takayuki Nojima; Lindsey A. Criswell; Richard Jordan; John S. Greenspan

OBJECTIVE To examine associations between labial salivary gland (LSG) histopathology and other phenotypic features of Sjögrens syndrome (SS). METHODS The database of the Sjögrens International Collaborative Clinical Alliance (SICCA), a registry of patients with symptoms of possible SS as well as those with obvious disease, was used for the present study. LSG biopsy specimens from SICCA participants were subjected to protocol-directed histopathologic assessments. Among the 1,726 LSG specimens exhibiting any pattern of sialadenitis, we compared biopsy diagnoses against concurrent salivary, ocular, and serologic features. RESULTS LSG specimens included 61% with focal lymphocytic sialadenitis (FLS; 69% of which had focus scores of ≥1 per 4 mm²) and 37% with nonspecific or sclerosing chronic sialadenitis (NS/SCS). Focus scores of ≥1 were strongly associated with serum anti-SSA/SSB positivity, rheumatoid factor, and the ocular component of SS, but not with symptoms of dry mouth or dry eyes. Those with positive anti-SSA/SSB were 9 times (95% confidence interval [95% CI] 7.4-11.9) more likely to have a focus score of ≥1 than were those without anti-SSA/SSB, and those with an unstimulated whole salivary flow rate of <0.1 ml/minute were 2 times (95% CI 1.7-2.8) more likely to have a focus score of ≥1 than were those with a higher flow rate, after controlling for other phenotypic features of SS. CONCLUSION Distinguishing FLS from NS/SCS is essential in assessing LSG biopsies, before determining focus score. A diagnosis of FLS with a focus score of ≥1 per 4 mm², as compared to FLS with a focus score of <1 or NS/SCS, is strongly associated with the ocular and serologic components of SS and reflects SS autoimmunity.


International Journal of Rheumatology | 2012

Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease.

Yasufumi Masaki; Nozomu Kurose; Motohisa Yamamoto; Hiroki Takahashi; Takako Saeki; Atsushi Azumi; Shinji Nakada; Shoko Matsui; Tomoki Origuchi; Susumu Nishiyama; Kazunori Yamada; Mitsuhiro Kawano; Akira Hirabayashi; Keita Fujikawa; Tomoko Sugiura; Masanobu Horikoshi; Naoto Umeda; Hiroshi Minato; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Takafumi Kawanami; Yoshimasa Fujita; Masao Tanaka; Toshihiro Fukushima; Katumi Eguchi; Susumu Sugai

IgG4-related disease is a new disease classification established in Japan in the 21st century. Patients with IgG4-related disease display hyper-IgG4-gammaglobulinemia, massive infiltration of IgG4+ plasma cells into tissue, and good response to glucocorticoids. Since IgG4 overexpression is also observed in other disorders, it is necessary to diagnose IgG4-related disease carefully and correctly. We therefore sought to determine cutoff values for serum IgG4 and IgG4/IgG and for IgG4+/IgG+ plasma cells in tissue diagnostic of IgG4-related disease. Patients and Methods. We retrospectively analyzed serum IgG4 concentrations and IgG4/IgG ratio and IgG4+/IgG+ plasma cell ratio in tissues of 132 patients with IgG4-related disease and 48 patients with other disorders. Result. Serum IgG4 >135  mg/dl demonstrated a sensitivity of 97.0% and a specificity of 79.6% in diagnosing IgG4-related disease, and serum IgG4/IgG ratios >8% had a sensitivity and specificity of 95.5% and 87.5%, respectively. IgG4+cell/IgG+ cell ratio in tissues >40% had a sensitivity and specificity of 94.4% and 85.7%, respectively. However, the number of IgG4+ cells was reduced in severely fibrotic parts of tissues. Conclusion. Although a recent unanimous consensus of all relevant researchers in Japan recently established the diagnostic criteria for IgG4-related disease, findings such as ours indicate that further discussion is needed.


International Journal of Hematology | 2016

Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version

Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki

TAFRO syndrome is a systemic inflammatory disorder characterized by thrombocytopenia, anasarca including pleural effusion and ascites, fever, renal insufficiency, and organomegaly including hepatosplenomegaly and lymphadenopathy. Its onset may be acute or sub-acute, but its etiology is undetermined. Although several clinical and pathological characteristics of TAFRO syndrome resemble those of multicentric Castleman disease (MCD), other specific features can differentiate between them. Some TAFRO syndrome patients have been successfully treated with glucocorticoids and/or immunosuppressants, including cyclosporin A, tocilizumab and rituximab, whereas others are refractory to treatment, and eventually succumb to the disease. Early and reliable diagnoses and early treatments with appropriate agents are essential to enhancing patient survival. The present article reports the 2015 updated diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, as formulated by Japanese research teams. These criteria and classification have been applied and retrospectively validated on clinicopathologic data of 28 patients with this and similar conditions (e.g. MCD with serositis and thrombocytopenia).


Surgery Today | 2001

A spontaneously ruptured gastric stromal tumor presenting as generalized peritonitis: report of a case.

Kazuo Kitabayashi; Takashi Seki; Keiko Kishimoto; Hitoshi Saitoh; Keiichi Ueno; Ichiroh Kita; Shigeki Takashima; Nozomu Kurose; Takayuki Nojima

Abstract Among the diverse clinical presentations of gastrointestinal stromal tumor (GIST), spontaneous rupture with peritonitis is extremely rare. We report herein the unusual case of a 75-year-old man found to have a spontaneously ruptured gastric stromal tumor after presenting with generalized peritonitis. The patient was brought to the emergency department of our hospital by ambulance, with generalized severe abdominal pain. On examination, his abdomen was extensively distended with generalized severe rebound tenderness. Abdominal computed tomography scan showed a giant mass arising from the anterior gastric wall with an irregular internal low-density area and a small amount of ascites. An emergency laparotomy revealed a ruptured gastric tumor with dissemination of its necrotic tissue throughout the peritoneal cavity. The tumor was excised together with normal gastric tissue around its base. The tumor, which was 15 × 11 × 4.4 cm in size, had a coarse laceration over its well-capsulated smooth serosal surface with massive necrosis and clotted blood inside. Immunohistochemical examination revealed positive reactivity to C-kit protein, which was consistent with the newly introduced diagnostic criteria of GIST. The patient had an uneventful postoperative course and remains well.


American Journal of Clinical Pathology | 2014

Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells

Hiroshi Minato; Nozomu Kurose; Mana Fukushima; Takayuki Nojima; Katsuo Usuda; Motoyasu Sagawa; Tsutomu Sakuma; Akishi Ooi; Isao Matsumoto; Makoto Oda; Yoshihiko Arano; Junzo Shimizu

OBJECTIVES To identify useful biomarkers for differentiating between malignant mesothelioma (MM) and reactive mesothelial cells (RMCs). METHODS Formalin-fixed, paraffin-embedded (FFPE) tissues from 34 MM and 40 RMC samples were analyzed using immunohistochemistry, and the findings were compared. RESULTS Positive markers for MM included insulin-like growth factor 2 messenger RNA binding protein 3 (IMP3), glucose transporter 1 (GLUT1), epithelial membrane antigen (EMA), and CD146, which showed sensitivities of 94%, 85%, 79%, and 71% and specificities of 78%, 100%, 88%, and 98%, respectively. In sarcomatoid MM, EMA had significantly lower expression than did IMP3, GLUT1, and CD146 (P < .001). The areas under receiver operating characteristic curves were the highest for IMP3 (0.95), followed by GLUT1 (0.93). When the optimal cutoff points for IMP3 (30%) and GLUT1 (10%) were used, the sensitivity of IMP3 and GLUT1 for MM was 100%, and the specificity of both for MM was 95%. CONCLUSIONS The combination of IMP3 and GLUT1 is most appropriate for distinguishing MM from RMC using FFPE sections.


Journal of Gastroenterology | 2005

Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobserver histological agreement on trimmed bile ducts

Yoh Zen; Kenichi Harada; Motoko Sasaki; Koichi Tsuneyama; Kazuhiro Matsui; Joji Haratake; Shotaro Sakisaka; Shiro Maeyama; Kazuhide Yamamoto; Masayuki Nakano; Kazuhide Shimamatsu; Masayoshi Kage; Nozomu Kurose; Akio Uchiyama; Yasuharu Kaizaki; Gotaro Toda; Yasuni Nakanuma

BackgroundPrimary biliary cirrhosis (PBC) is histopathologically characterized by chronic nonsuppurative destructive cholangitis and ductopenia of interlobular bile ducts. Bile duct injury is also often encountered in chronic viral hepatitis (CVH) and in autoimmune hepatitis (AIH).MethodsIn this study, we performed interobserver agreement analysis on 90 injured bile ducts from liver specimens of PBC (17 cases), CVH (26 cases), and AIH (18 cases), with 30 bile ducts chosen from each disease group. Digital images of bile ducts with minimal periductal elements were recorded in CD-ROM format and sent to 14 observers (six special hepatopathologists, four local hepatopathologists, and four general pathologists). We analyzed the following issues: (1) diagnostic accuracy of PBC, based only on bile duct lesions; (2) classification of bile duct lesions in AIH cases as destructive cholangitis equivalent to PBC-associated injury, or not.ResultsThe diagnostic accuracy of PBC cases with severe bile duct injuries was very high (over 80%), although the accuracy in cases with only mild bile duct injuries was low (50% or less). For AIH, each observer classified 9 of the 30 bile ducts, on average, as destructive cholangitis.ConclusionsThis study revealed that 66.9% of PBC cases could be diagnosed based on trimmed bile ducts alone. Bile duct injury similar to that in PBC could be encountered in AIH.


Annals of the Rheumatic Diseases | 2015

The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome

Alan N. Baer; Mara McAdams DeMarco; Stephen Shiboski; Mi Y. Lam; Stephen Challacombe; Troy E. Daniels; Yi Dong; John S. Greenspan; Bruce Kirkham; Hector Lanfranchi; Morten Schiødt; Muthiah Srinivasan; Hisanori Umehara; Frederick B. Vivino; Cristina F. Vollenweider; Yan Zhao; Lindsey A. Criswell; Caroline H. Shiboski; Darren P. Cox; Richard Jordan; D. Lee; Yvonne DeSouza; D. Drury; A. Do; L. Scott; M. Lam; J. Nespeco; J. Whiteford; M. Margaret; I. Adler

Objective To determine whether the Sjögrens syndrome B (SSB)-positive/Sjögrens syndrome A (SSA)-negative antibody profile is associated with key phenotypic features of SS. Methods Among registrants in the Sjögrens International Collaborative Clinical Alliance (SICCA) with possible or established SS, we compared anti-SSA/anti-SSB reactivity profiles against concurrent phenotypic features. We fitted logistic regression models to explore the association between anti-SSA/anti-SSB reactivity profile and each key SS phenotypic feature, controlling for potential confounders. Results Among 3297 participants, 2061 (63%) had negative anti-SSA/anti-SSB, 1162 (35%) had anti-SSA with or without anti-SSB, and 74 (2%) anti-SSB alone. Key SS phenotypic features were more prevalent and had measures indicative of greater disease activity in those participants with anti-SSA, either alone or with anti-SSB, than in those with anti-SSB alone or negative SSA/SSB serology. These between-group differences were highly significant and not explained by confounding by age, race/ethnicity or gender. Participants with anti-SSB alone were comparable to those with negative SSA/SSB serology in their association with these key phenotypic features. Among SICCA participants classified with SS on the basis of the American-European Consensus Group or American College of Rheumatology criteria, only 2% required the anti-SSB-alone test result to meet these criteria. Conclusions The presence of anti-SSB, without anti-SSA antibodies, had no significant association with SS phenotypic features, relative to seronegative participants. The solitary presence of anti-SSB antibodies does not provide any more support than negative serology for the diagnosis of SS. This serological profile should thus be interpreted cautiously in clinical practice and potentially eliminated from future classification criteria.


Pathology International | 2009

Adenomatoid tumor of the pleura.

Hiroshi Minato; Takayuki Nojima; Nozomu Kurose; Eriko Kinoshita

A case of adenomatoid tumor of the pleura is reported, and its differential diagnosis from benign and malignant pleural lesions is discussed. A small pleural nodule was incidentally found during a thoracic operation in a 54‐year‐old woman with esophageal cancer. The patient had no history of exposure to asbestos, and was well with no sign of recurrence 14 months after the operation. A 7 mm, circumscribed tumor had characteristic features of adenomatoid tumor. The tumor was composed of an aggregation of irregularly shaped tubulocystic spaces with fibrous stoma. The spaces were lined by flattened and occasional cuboidal epithelioid cells with cytoplasmic vacuolization, and several spaces contained pale blue mucinous fluid. On immunohistochemistry the tumor cells were positive for AE1/AE3, CAM5.2, vimentin, cytokeratin 5/6, D2‐40, calretinin, thrombomodulin, and WT‐1, but negative for CEA, Leu M1 (CD15), thyroid transcription factor‐1, epithelial membrane antigen, desmin, glucose transporter‐1 (GLUT‐1), CD31, and CD34. The MIB‐1 (Ki‐67) labeling index was 1–2%, indicating low proliferative activity. Adenomatoid tumor of the pleura is rare, and the pathogenesis has not been elucidated. Recognition of these benign mesothelial lesions in the pleura is important to avoid misdiagnosis. The immunohistochemistry in the present case supports its mesothelial origin.

Collaboration


Dive into the Nozomu Kurose's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yasufumi Masaki

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Minato

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Mariko Nakano

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Satoko Nakada

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Sohsuke Yamada

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Manabu Yamashita

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Takafumi Kawanami

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Akihiro Shioya

Kanazawa Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge